



**FOR IMMEDIATE RELEASE**

CMD BIOSCIENCE ANNOUNCES THE RELEASE OF CMDINVENTUS<sup>SM</sup>, A COMPUTATIONAL PLATFORM SPECIFICALLY DEVELOPED TO ENABLE RATIONAL PEPTIDE DISCOVERY.

**New Haven, Conn., June 3, 2011** -- CMDBioscience, a CT based biotechnology company specializing in computer-aided peptide drug discovery, announced today the release of CMDInventus<sup>SM</sup>, a modular computational discovery platform specifically developed to enable rational peptide design.

Based on the research of founder and CEO Dr. Joseph Audie, CMDInventus<sup>SM</sup> offers pharmaceutical, biotech and life science companies a ground breaking tool to assist with their peptide discovery projects. CMDInventus<sup>SM</sup> has been fully validated by multiple research projects, including a recent project aimed at identifying novel dengue virus anti-infective agents. Using CMDInventus, CMDBioscience scientists were able to model a key dengue structural motif and rationally design small peptides that targeted the motif. The project, completed in seven weeks time, involved the explicit consideration of 480,000 peptide sequences and ultimately converged on the 27 most promising peptides. Subsequent synthesis and experimental testing revealed excellent anti-infective activity for 5 of the designed peptides.

"We are very excited about the release of CMDInventus<sup>SM</sup>. This validated platform technology, especially when combined with our expertise, offers partner companies the unique ability to significantly improve their peptide discovery outcomes and to take advantage of the rapidly growing multi-billion dollar peptide market", said Dr Joseph Audie, CEO of CMDBioscience. Dr. Audie further commented that with the release of CMDInventus<sup>SM</sup>, the promise of using computation to accelerate novel peptide discovery becomes a reality. Finally, Dr. Audie stated, "CMDInventus<sup>SM</sup> will help our partners obtain a competitive advantage in the ever expanding peptide market."

**About:** CMDBioscience is a computational biotechnology company that specializes in the computer-enabled analysis, modeling and design of therapeutic protein-peptide interactions or structure-based peptide design. Using structure-based peptide design, CMD scientists can help partner organizations efficiently identify novel peptide hits and leads, understand the structural basis of protein-peptide interactions, and rationally optimize peptide leads.

**CMD Bioscience contact:**

[www.cmdbioscience.com](http://www.cmdbioscience.com)

Joseph Audie, PhD CEO

joseph.audie@cmdbioscience.com

Office 203-298-4251

Fax 203-298-4252